Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow BMY
Bristol Myers Squibb Company (BMY) EV/FCF
As of 9 October 2026, Bristol Myers Squibb Company (BMY) trades at a EV/FCF of 13.4×. Over the past ten years it has ranged from 7.8× (October 2025) to 389× (June 2016); the current reading is higher than 45% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 11.2× | 1.97% |
| FY2024 | 11.0× | 1.89% |
| FY2023 | 10.8× | (29.85%) |
| FY2022 | 15.4× | 41.26% |
| FY2021 | 10.9× | (17.12%) |
| FY2020 | 13.2× | (31.11%) |
| FY2019 | 19.1× | 39.86% |
| FY2018 | 13.7× | (43.53%) |
| FY2017 | 24.2× | (55.32%) |
| FY2016 | 54.1× | (40.63%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 13.1× | (1.10%) |
| Mar 2026 | 13.2× | 17.92% |
| Dec 2025 | 11.2× | 38.15% |
| Sep 2025 | 8.1× | (8.76%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi compare | 7.8× |
| BMY Bristol Myers Squibb Company | 13.4× |
| GSK GSK PLC Sponsored ADR compare | 14.8× |
| GILD Gilead Sciences, Inc. compare | 16.3× |
| NVS Novartis AG compare | 20.6× |
| PFE Pfizer Inc. compare | 20.9× |
| NVO Novo Nordisk A/S compare | 24.4× |
| AMGN Amgen Inc. compare | 27.4× |
| AZN AstraZeneca PLC compare | 43.3× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement